Multiple aberrant hormone receptors in Cushing's syndrome

European Journal of Endocrinology

Volumn 173, Issue 4, 2015, Pages M45-M60

  El Ghorayeb, Nada ^a   Bourdeau, Isabelle ^a   Lacroix, André ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HYDROCORTISONE; LIGAND; BETA ADRENERGIC RECEPTOR; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON RECEPTOR; HORMONE RECEPTOR; LUTEINIZING HORMONE RECEPTOR; MELANOCORTIN 2 RECEPTOR; SEROTONIN 4 RECEPTOR; VASOPRESSIN RECEPTOR;

ADRENAL HYPERPLASIA; ADRENAL TUMOR; AUTOCRINE EFFECT; BILATERAL MACRONODULAR ADRENAL HYPERPLASIA; CONFERENCE PAPER; CUSHING SYNDROME; DRUG TARGETING; FAMILIAL DISEASE; HUMAN; HYPERALDOSTERONISM; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SCREENING; ZONA FASCICULATA; ADENOMA; GENE EXPRESSION; METABOLISM;

ADENOMA; ADRENAL GLAND NEOPLASMS; CUSHING SYNDROME; CYCLIC AMP; GENE EXPRESSION; HUMANS; RECEPTOR, MELANOCORTIN, TYPE 2; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; RECEPTORS, LH; RECEPTORS, SEROTONIN, 5-HT4; RECEPTORS, VASOPRESSIN;

EID: 84942811612     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0200     Document Type: Conference Paper

References (149)

1. Newell-Price J, Bertagna X, Grossman AB & Nieman LK. Cushing's syndrome. Lancet 2006 367 1605-1617. (doi:10.1016/S0140-6736(06)68699-6.
2. Lacroix A, Feelders RA, Stratakis CE & Niemann LK. Cushing's syndrome. Lancet. 2015 In press. (doi:10.1016/S0140-6736(14)61375-1.
3. Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. Journal of Clinical Endocrinology and Metabolism 2011 96 1223-1236. (doi:10.1210/jc.2010-2722.
4. Chan LF, Metherell LA & Clark AJ. Effects of melanocortins on adrenal gland physiology. European Journal of Pharmacology 2011 660 171-180. (doi:10.1016/j.ejphar.2010.11.041.
5. De-Joussineau C, Sahut-Barnola I, Levy I, Saloustros E, Val P, Stratakis CA & Martinez A. The cAMP pathway and the control of adrenocortical development and growth. Molecular and Cellular Endocrinology 2012 351 28-36. (doi:10.1016/j.mce.2011.10.006.
6. Pearce LR, Komander D & Alessi DR. The nuts and bolts of AGC protein kinases. Nature Reviews. Molecular Cell Biology 2010 11 9-22. (doi:10.1038/nrm2822.
7. Lacroix A, Ndiaye N, Tremblay J & Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocrine Reviews 2001 22 75-110. (doi:10.1210/edrv.22.1.0420.
8. Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. New England Journal of Medicine 2014 370 1019-1028. (doi:10.1056/NEJMoa1310359.
9. Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, Arnaldi G, Quinkler M, Rayes N, Tabarin A, Laure Jullie M et al. Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. Journal of Clinical Endocrinology and Metabolism 2014 99 E2093-E2100. (doi:10.1210/jc.2014-2152.
10. Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, Zhou W, Li X, Zhong X, Lei Y et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. Science 2014 344 913-917. (doi:10.1126/science.1249480.
11. Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW, Korah R, Suttorp AC, Dietrich D et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nature Genetics 2014 46 613-617. (doi:10.1038/ng.2956.
12. Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T, Shiraishi Y, Yoshida K, Nagata Y, Sato-Otsubo A, Yoshizato T et al. Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science 2014 344 917-920. (doi:10.1126/science.1252328.
13. Groussin L, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton JP, Bertagna X & Bertherat J. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. Journal of Clinical Endocrinology and Metabolism 2002 87 4324-4329. (doi:10.1210/jc.2002-020592.
14. Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney JA, Luton JP et al. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. American Journal of Human Genetics 2002 71 1433-1442. (doi:10.1086/344579.
15. Groussin L, Horvath A, Jullian E, Boikos S, Rene-Corail F, Lefebvre H, Cephise-Velayoudom FL, Vantyghem MC, Chanson P, Conte- Devolx B et al. A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. Journal of Clinical Endocrinology and Metabolism 2006 91 1943-1949. (doi:10.1210/jc.2005-2708.
16. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS & Stratakis CA. Mutations of the gene encoding the protein kinase A type I-a regulatory subunit in patients with the Carney complex. Nature Genetics 2000 26 89-92. (doi:10.1038/79238.
17. Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP et al. A genomewide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nature Genetics 2006 38 794-800. (doi:10.1038/ng1809.
18. Rothenbuhler A, Horvath A, Libe R, Faucz FR, Fratticci A, Raffin Sanson ML, Vezzosi D, Azevedo M, Levy I, Almeida MQ et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clinical Endocrinology 2012 77 195-199. (doi:10.1111/j.1365-2265.2012.04366.x.
19. Mauras N & Blizzard RM. The McCune-Albright syndrome. Acta Endocrinologica. Supplementum 1986 279 207-217.
20. Spiegel AM & Weinstein LS. Inherited diseases involving G proteins and G protein-coupled receptors. Annual Review of Medicine 2004 55 27-39. (doi:10.1146/annurev.med.55.091902.103843.
21. Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC, Lucon AM & Mendonca BB. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. Journal of Clinical Endocrinology and Metabolism 2003 88 2147-2151. (doi:10.1210/jc.2002-021362.
22. Brown RJ, Kelly MH & Collins MT. Cushing syndrome in the McCune- Albright syndrome. Journal of Clinical Endocrinology and Metabolism 2010 95 1508-1515. (doi:10.1210/jc.2009-2321.
23. Latronico AC, Reincke M, Mendonca BB, Arai K, Mora P, Allolio B, Wajchenberg BL, Chrousos GP & Tsigos C. No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. Journal of Clinical Endocrinology and Metabolism 1995 80 875-877. (doi:10.1210/jcem.80.3.7883845.
24. Light K, Jenkins PJ, Weber A, Perrett C, Grossman A, Pistorello M, Asa SL, Clayton RN & Clark AJ. Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia? Life Sciences 1995 56 1523-1527. (doi:10.1016/0024-3205(95)00114-L.
25. Swords FM, Baig A, Malchoff DM, Malchoff CD, Thorner MO, King PJ, Hunyady L & Clark AJ. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Molecular Endocrinology 2002 16 2746-2753. (doi:10.1210/me.2002-0099.
26. Swords FM, Noon LA, King PJ & Clark AJ. Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene. Molecular and Cellular Endocrinology 2004 213 149-154. (doi:10.1016/j.mce.2003.10.052.
27. Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ, Tremblay J, Hamet P, Bourdeau I, Zerbini MC, Pereira MA et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2014 99 E1501-E1509. (doi:10.1210/jc.2013-4237.
28. Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, Berthon A, Libe R, Assie G, Espiard S et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. Journal of Clinical Endocrinology and Metabolism 2014 99 E1113-E1119. (doi:10.1210/jc.2013-4280.
29. Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C, Oftedal BE, Cutfield R, Adelson DL et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2014 99 E1784-E1792. (doi:10.1210/jc.2014-1265.
30. Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefevre L, Sibony M, Guignat L et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. New England Journal of Medicine 2013 369 2105-2114. (doi:10.1056/NEJMoa1304603.
31. Espiard S, Drougat L, Libe R, Assie G, Perlemoine K, Guignat L, Barrande G, Brucker-Davis F, Doullay F, Lopez S et al. ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences. Journal of Clinical Endocrinology and Metabolism 2015 100 E926-E930. (doi:10.1210/jc.2014-4204.
32. Lee S, Hwang R, Lee J, Rhee Y, Kim DJ, Chung UI & Lim SK. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clinical Endocrinology 2005 63 625-630. (doi:10.1111/j.1365-2265.2005.02387.x.
33. Elbelt U, Trovato A, Kloth M, Gentz E, Finke R, Spranger J, Galas D, Weber S, Wolf C, Konig K et al. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. Journal of Clinical Endocrinology and Metabolism 2015 100 E119-E128. (doi:10.1210/jc.2014-2648.
34. Louiset E, Duparc C, Young J, Renouf S, Tetsi Nomigni M, Boutelet I, Libe R, Bram Z, Groussin L, Caron P et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. New England Journal of Medicine 2013 369 2115-2125. (doi:10.1056/NEJMoa1215245.
35. Lefebvre H, Duparc C, Prevost G, Zennaro MC, Bertherat J & Louiset E. Paracrine control of steroidogenesis by serotonin in adrenocortical neoplasms. Molecular and Cellular Endocrinology 2015 408 198-204. (doi:10.1016/j.mce.2014.11.013.
36. Schorr I & Ney RL. Abnormal hormone responses of an adrenocortical cancer adenyl cyclase. Journal of Clinical Investigation 1971 50 1295-1300. (doi:10.1172/JCI106608.
37. Hamet P, Larochelle P, Franks DJ, Cartier P & Bolte E. Cushing syndrome with food-dependent periodic hormonogenesis. Clinical and Investigative Medicine 1987 10 530-533.
38. Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F & Taillefer R. Gastric inhibitory polypeptidedependent cortisol hypersecretion - A new cause of Cushing's syndrome. New England Journal of Medicine 1992 327 974-980. (doi:10.1056/NEJM199210013271402.
39. Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM & Mahoudeau J. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. New England Journal of Medicine 1992 327 981-986. (doi:10.1056/NEJM199210013271403.
40. Lacroix A, Baldacchino V, Bourdeau I, Hamet P & Tremblay J. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends in Endocrinology and Metabolism 2004 15 375-382. (doi:10.1016/S1043-2760(04)00188-2.
41. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J & Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clinical Endocrinology 2010 73 1-15. (doi:10.1111/j.1365-2265.2009.03689.x.
42. Lacroix A & Bourdeau I. Bilateral adrenal Cushing's syndrome: macronodular adrenal hyperplasia and primary pigmented nodular adrenocortical disease. Endocrinology and Metabolism Clinics of North America 2005 34 441-458, x. (doi:10.1016/j.ecl.2005.01.004.
43. Mermejo LM, Mazzuco TL, Grunenwald S, Fragoso MC, Bourdeau I & Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Endocrinology and Metabolism 2011 26 1. (doi:10.3803/EnM.2011.26.1.1.
44. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Practice & Research. Clinical Endocrinology & Metabolism 2009 23 245-259. (doi:10.1016/j.beem.2008.10.011.
45. Mircescu H, Jilwan J, N'Diaye N, Bourdeau I, Tremblay J, Hamet P & Lacroix A. Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome? Journal of Clinical Endocrinology and Metabolism 2000 85 3531-3536. (doi:10.1210/jcem.85.10.6865.
46. Reznik Y, Lefebvre H, Rohmer V, Charbonnel B, Tabarin A, Rodien P, Lecomte P, Bardet S, Coffin C, Mahoudeau J et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clinical Endocrinology 2004 61 311-319. (doi:10.1111/j.1365-2265.2004.02048.x.
47. Libe R, Coste J, Guignat L, Tissier F, Lefebvre H, Barrande G, Ajzenberg C, Tauveron I, Clauser E, Dousset B et al. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. European Journal of Endocrinology 2010 163 129-138. (doi:10.1530/EJE-10-0195.
48. Hofland J, Hofland LJ, van Koetsveld PM, Steenbergen J, de-Herder WW, van-Eijck CH, de-Krijger RR, van-Nederveen FH, van-Aken MO, de-Groot JW et al. ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of argininevasopressin type 1a receptor to 11b-hydroxylase. Orphanet Journal of Rare Diseases 2013 8 142. (doi:10.1186/1750-1172-8-142.
49. Hsiao HP, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A & Stratakis CA. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropinindependent macronodular adrenal hyperplasia compared with other adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2009 94 2930-2937. (doi:10.1210/jc.2009-0516.
50. Bourdeau I, D'Amour P, Hamet P, Boutin JM & Lacroix A. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2001 86 5534-5540. (doi:10.1210/jcem.86.11.8062.
51. Tatsuno I, Uchida D, Tanaka T, Koide H, Shigeta A, Ichikawa T, Sasano H & Saito Y. Vasopressin responsiveness of subclinical Cushing's syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clinical Endocrinology 2004 60 192-200. (doi:10.1046/j.1365-2265.2003.01963.x.
52. Dall'Asta C, Ballare E, Mantovani G, Ambrosi B, Spada A, Barbetta L, Colombo P, Travaglini P, Loli P & Beck-Peccoz P. Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: in vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Hormone and Metabolic Research 2004 36 578-583. (doi:10.1055/s-2004-825797.
53. Joubert M, Louiset E, Rego JL, Contesse V, Kong LC, Benhaim A, Mittre H, Lefebvre H, Reznik Y & Group RS. Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors? Clinical Endocrinology 2008 68 692-699. (doi:10.1111/j.1365-2265.2007.03106.x.
54. Albiger NM, Occhi G, Mariniello B, Iacobone M, Favia G, Fassina A, Faggian D, Mantero F & Scaroni C. Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. European Journal of Endocrinology 2007 157 771-778. (doi:10.1530/EJE-07-0253.
55. Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Groussin L, Emy P, Bertagna X, Kuhn JM, Vaudry H et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitorypolypeptide-dependent hypercortisolism. Journal of Clinical Endocrinology and Metabolism 2005 90 1302-1310. (doi:10.1210/jc.2004-1256.
56. Lampron A, Bourdeau I, Hamet P, Tremblay J & Lacroix A. Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- And adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 3611-3618. (doi:10.1210/jc.2006-0221.
57. N'Diaye N, Hamet P, Tremblay J, Boutin JM, Gaboury L & Lacroix A. Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1999 84 2616-2622. (doi:10.1210/jcem.84.8.5930.
58. Chabre O, Liakos P, Vivier J, Bottari S, Bachelot I, Chambaz EM, Feige JJ & Defaye G. Gastric inhibitory polypeptide (GIP) stimulates cortisol secretion, cAMP production and DNA synthesis in an adrenal adenoma responsible for food-dependent Cushing's syndrome. Endocrine Research 1998 24 851-856. (doi:10.3109/07435809809032696.
59. Swords FM, Aylwin S, Perry L, Arola J, Grossman AB, Monson JP & Clark AJ. The aberrant expression of the gastric inhibitory polypeptide (GIP) receptor in adrenal hyperplasia: does chronic adrenocorticotropin exposure stimulate up-regulation of GIP receptors in Cushing's disease? Journal of Clinical Endocrinology and Metabolism 2005 90 3009- 3016. (doi:10.1210/jc.2004-0946.
60. Antonini SR, Baldacchino V, Tremblay J, Hamet P & Lacroix A. Expression of ACTH receptor pathway genes in glucose-dependent insulinotrophic peptide (GIP)-dependent Cushing's syndrome. Clinical Endocrinology 2006 64 29-36. (doi:10.1111/j.1365-2265.2005.02411.x.
61. Baldacchino V, Oble S, Decarie PO, Bourdeau I, Hamet P, Tremblay J & Lacroix A. The Sp transcription factors are involved in the cellular expression of the human glucose-dependent insulinotropic polypeptide receptor gene and overexpressed in adrenals of patients with Cushing's syndrome. Journal of Molecular Endocrinology 2005 35 61-71. (doi:10.1677/jme.1.01765.
62. N'Diaye N, Tremblay J, Hamet P, De Herder WW & Lacroix A. Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 2781-2785. (doi:10.1210/jcem.83.8.5038.
63. Mazzuco TL, Chabre O, Sturm N, Feige JJ & Thomas M. Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model. Endocrinology 2006 147 782-790. (doi:10.1210/en.2005-0921.
64. Lacroix A, Hamet P & Boutin JM. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome. New England Journal of Medicine 1999 341 1577-1581. (doi:10.1056/NEJM199911183412104.
65. Chui MH, Ozbey NC, Ezzat S, Kapran Y, Erbil Y & Asa SL. Case report: adrenal LH/hCG receptor overexpression and gene amplification causing pregnancy-induced Cushing's syndrome. Endocrine Pathology 2009 20 256-261. (doi:10.1007/s12022-009-9090-2.
66. Feelders RA, Lamberts SW, Hofland LJ, van-Koetsveld PM, Verhoef-Post M, Themmen AP, de-Jong FH, Bonjer HJ, Clark AJ, van-der-Lely AJ et al. Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. Journal of Clinical Endocrinology and Metabolism 2003 88 230-237. (doi:10.1210/jc.2002-020621.
67. Bugalho MJ, Li X, Rao CV, Soares J & Sobrinho LG. Presence of a Gs a mutation in an adrenal tumor expressing LH/hCG receptors and clinically associated with Cushing's syndrome. Gynecological Endocrinology 2000 14 50-54. (doi:10.3109/09513590009167660.
68. Kero J, Poutanen M, Zhang FP, Rahman N, McNicol AM, Nilson JH, Keri RA & Huhtaniemi IT. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. Journal of Clinical Investigation 2000 105 633-641. doi:10.1172/JCI7716.
69. Assie G, Louiset E, Sturm N, Rene-Corail F, Groussin L, Bertherat J, Thomas M, Lefebvre H, Feige JJ, Clauser E et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropinindependent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2010 95 E253-E262. (doi:10.1210/jc.2009-2281.
70. Jaiswal N & Sharma RK. Dual regulation of adenylate cyclase and guanylate cyclase: a 2-adrenergic signal transduction in adrenocortical carcinoma cells. Archives of Biochemistry and Biophysics 1986 249 616-619. (doi:10.1016/0003-9861(86)90041-X.
71. Louiset E, Isvi K, Gasc JM, Duparc C, Cauliez B, Laquerriere A, Kuhn JM & Lefebvre H. Ectopic expression of serotonin7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol. Endocrine- Related Cancer 2008 15 1025-1034. (doi:10.1677/ERC-08-0085.
72. Contesse V, Reznik Y, Louiset E, Duparc C, Cartier D, Sicard F, Laquerriere A, Parmentier F, Kuhn JM, Vaudry H et al. Abnormal sensitivity of cortisol-producing adrenocortical adenomas to serotonin: in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 2005 90 2843-2850. doi:10.1210/jc.2004-2476.
73. Matsukura S, Kakita T, Sueoka S, Yoshimi H, Hirata Y, Yokota M & Fujita T. Multiple hormone receptors in the adenylate cyclase of human adrenocortical tumors. Cancer Research 1980 40 3768-3771.
74. De-Miguel V, Redal MA, Viale ML, Kahan M, Glerean M, Beskow A & Fainstein Day P. Aberrant expression of glucagon receptors in adrenal glands of a patient with Cushing's syndrome and ACTH-independent macronodular adrenal hyperplasia. Medicina 2010 70 254-256.
75. Louiset E, Duparc C, Groussin L, Gobet F, Desailloud R, Barrande G, Reznik Y, Bertherat J, Prevost G & Lefebvre H. Abnormal sensitivity to glucagon and related peptides in primary adrenal Cushing's syndrome. Hormone and Metabolic Research 2014 46 876-882. (doi:10.1055/s-0034-1384522.
76. Xekouki P, Bram Z, Louiset E, Avgeropoulos D, Nesterova MV, Sinaii N, Lefebvre H & Stratakis CA. Expression of somatostatin receptors in normal adrenal and in primary pigmented nodular adrenocortical disease (PPNAD). A possible new use for somatostatin analogues. The Endocrine Society's 95th Annual Meeting and Expo, June 15-18, 2013 - San Francisco. Abstract, pp MON-8-MON-8.
77. Gagliardi L, Hotu C, Casey G, Braund WJ, Ling KH, Dodd T, Manavis J, Devitt PG, Cutfield R, Rudzki Z et al. Familial vasopressin-sensitive ACTH-independent macronodular adrenal hyperplasia (VPs-AIMAH): clinical studies of three kindreds. Clinical Endocrinology 2009 70 883-891. (doi:10.1111/j.1365-2265.2008.03471.x.
78. Miyamura N, Taguchi T, Murata Y, Taketa K, Iwashita S, Matsumoto K, Nishikawa T, Toyonaga T, Sakakida M & Araki E. Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine 2002 19 319-326. (doi:10.1385/ENDO:19:3:319.
79. Vezzosi D, Cartier D, Regnier C, Otal P, Bennet A, Parmentier F, Plantavid M, Lacroix A, Lefebvre H & Caron P. Familial adrenocorticotropin- independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. European Journal of Endocrinology 2007 156 21-31. (doi:10.1530/eje.1.02324.
80. Findlay JC, Sheeler LR, Engeland WC & Aron DC. Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1993 76 189-191. (doi:10.1210/jcem.76.1.8380604.
81. Imohl M, Koditz R, Stachon A, Muller KM, Nicolas V, Pfeilschifter J & Krieg M. Catecholamine-dependent hereditary Cushing's syndrome -follow-up after unilateral adrenalectomy. Medizinische Klinik 2002 97 747-753. (doi:10.1007/s00063-002-1220-2.
82. Minami S, Sugihara H, Sato J, Tatsukuchi A, Sugisaki Y, Sasano H & Wakabayashi I. ACTH independent Cushing's syndrome occurring in siblings. Clinical Endocrinology 1996 44 483-488. (doi:10.1046/j.1365-2265.1996.682504.x.
83. Nies C, Bartsch DK, Ehlenz K, Wild A, Langer P, Fleischhacker S & Rothmund M. Familial ACTH-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Experimental and Clinical Endocrinology & Diabetes 2002 110 277-283. (doi:10.1055/s-2002-34590.
84. Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Perraudin V, Bertherat J & Lefebvre H. Expression of vasopressin receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing's syndrome: molecular, immunohistochemical and pharmacological correlates. Journal of Endocrinology 2008 196 1-9. (doi:10.1677/JOE-07-0413.
85. Cartier D, Lihrmann I, Parmentier F, Bastard C, Bertherat J, Caron P, Kuhn JM, Lacroix A, Tabarin A, Young J et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropinindependent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 248-254. (doi:10.1210/jc.2002-021107.
86. Louiset E, Cartier D, Contesse V, Duparc C, Lihrmann I, Young J, Bertherat J, Reznik Y, Kuhn JM, Laquerriere A et al. Paradoxical inhibitory effect of serotonin on cortisol production from adrenocortical lesions causing Cushing's syndrome. Endocrine Research 2004 30 951-954. (doi:10.1081/ERC-200044170.
87. Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Barrande G, Bertherat J, Vaudry H & Lefebvre H. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 4578-4586. (doi:10.1210/jc.2006-0538.
88. Fujii H, Tamamori-Adachi M, Uchida K, Susa T, Nakakura T, Hagiwara H, Iizuka M, Okinaga H, Tanaka Y & Okazaki T. Marked cortisol production by intracrine ACTH in GIP-treated cultured adrenal cells in which the GIP receptor was exogenously introduced. PLoS ONE 2014 9 e110543. (doi:10.1371/journal.pone.0110543).
89. Lacroix A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. New England Journal of Medicine 2013 369 2147-2149(doi:10.1056/NEJMe1312792).
90. Stratakis CA, Sarlis N, Kirschner LS, Carney JA, Doppman JL, Nieman LK, Chrousos GP & Papanicolaou DA. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Annals of Internal Medicine 1999 131 585-591. (doi:10.7326/0003-4819-131-8-199910190-00006.
91. Louiset E, Stratakis CA, Perraudin V, Griffin KJ, Libe R, Cabrol S, Feve B, Young J, Groussin L, Bertherat J et al. The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptormediated effect of dexamethasone on protein kinase A catalytic subunits. Journal of Clinical Endocrinology and Metabolism 2009 94 2406-2413. (doi:10.1210/jc.2009-0031.
92. Bourdeau I, Lacroix A, Schurch W, Caron P, Antakly T & Stratakis CA. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. Journal of Clinical Endocrinology and Metabolism 2003 88 3931-3937. (doi:10.1210/jc.2002-022001.
93. Caticha O, Odell WD, Wilson DE, Dowdell LA, Noth RH, Swislocki AL, Lamothe JJ & Barrow R. Estradiol stimulates cortisol production by adrenal cells in estrogen-dependent primary adrenocortical nodular dysplasia. Journal of Clinical Endocrinology and Metabolism 1993 77 494-497. (doi:10.1210/jcem.77.2.8345057.
94. Bram Z, Wils J, Ragazzon B, Risk-RabinM, Libe R, Young J, Vantyghem M-C, Martinez A, Stratakis CA, Bertherat JY, et al. b-estradiol (E2) stimulates cortisol secretion in primary pigmented nodular adrenal disease: an explanation for the increased frequency of Cushing's syndrome in female patients with Carney complex. The Endocrine Society's 96th Meeting and 16th International Congress of Endocrinology (ICE-ENDO 2014), Chicago, June 21-24 2014 - Abstract OR14-12.
95. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ et al. KC channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011 331 768-772. (doi:10.1126/science.1198785.
96. Scholl UI, Goh G, Stolting G, de-Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW et al. Somatic and germline CACNA1D calcium channel mutations in aldosteroneproducing adenomas and primary aldosteronism. Nature Genetics 2013 45 1050-1054. (doi:10.1038/ng.2695.
97. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics 2013 45 pp 440-444, 444e441-442. (doi:10.1038/ng.2550.
98. Zennaro MC, Boulkroun S & Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. Journal of Endocrinology 2015 224 R63-R77. (doi:10.1530/JOE-14-0597.
99. ZwermannO, Suttmann Y, Bidlingmaier M, Beuschlein F & Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. European Journal of Endocrinology 2009 160 443-451. (doi:10.1530/EJE-08-0711.
100. Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B & Reincke M. Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. Clinical Endocrinology 2001 54 627-632. (doi:10.1046/j.1365-2265.2001.01253.x.
101. Ye P, Mariniello B, Mantero F, Shibata H & Rainey WE. G-proteincoupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. Journal of Endocrinology 2007 195 39-48. (doi:10.1677/JOE-07-0037.
102. Arnaldi G, Mancini V, Costantini C, Giovagnetti M, Petrelli M, Masini A, Bertagna X & Mantero F. ACTH receptor mRNA in human adrenocortical tumors: overexpression in aldosteronomas. Endocrine Research 1998 24 845-849. (doi:10.3109/07435809809032695.
103. Lefebvre H, Cartier D, Duparc C, Lihrmann I, Contesse V, Delarue C, Godin M, Fischmeister R, Vaudry H & Kuhn JM. Characterization of serotonin(4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 2002 87 1211-1216. (doi:10.1210/jcem.87.3.8327.
104. Saner-Amigh K, Mayhew BA, Mantero F, Schiavi F, White PC, Rao CV & Rainey WE. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 2006 91 1136-1142. (doi:10.1210/jc.2005-1298.
105. Mune T, Murase H, Yamakita N, Fukuda T, Murayama M, Miura A, Suwa T, Hanafusa J, Daido H, Morita H et al. Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2002 87 5706-5713. (doi:10.1210/jc.2002-020067.
106. Perraudin V, Delarue C, Lefebvre H, Do Rego JL, Vaudry H & Kuhn JM. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. Journal of Clinical Endocrinology and Metabolism 2006 91 1566-1572. (doi:10.1210/jc.2005-1453.
107. Rossi GP, Ganzaroli C, Cesari M, Maresca A, Plebani M, Nussdorfer GG & Pessina AC. Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovascular Research 2003 57 277-283. (doi:10.1016/S0008-6363(02)00658-2.
108. Cartier D, Jegou S, Parmentier F, Lihrmann I, Louiset E, Kuhn JM, Bastard C, Plouin PF, Godin M, Vaudry H et al. Expression profile of serotonin4 (5-HT4) receptors in adrenocortical aldosterone-producing adenomas. European Journal of Endocrinology 2005 153 939-947. (doi:10.1530/eje.1.02051.
109. Gross MD, Grekin RJ, Gniadek TC & Villareal JZ. Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism. New England Journal of Medicine 1981 305 181-185. (doi:10.1056/NEJM198107233050401.
110. Mantero F, Rocco S, Opocher G, Armanini D, Boscaro M & D'Agostino D. Effect of ketanserin in primary aldosteronism. Journal of Cardiovascular Pharmacology 1985 7 (Suppl 7) S172-S175. (doi:10.1097/00005344-198500077-00048.
111. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA & Vinson GP. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocrine Reviews 1998 19 101-143. (doi:10.1210/edrv.19.2.0326.
112. Lefebvre H, Compagnon P, Contesse V, Delarue C, Thuillez C, Vaudry H & Kuhn JM. Production and metabolism of serotonin (5-HT) by the human adrenal cortex: paracrine stimulation of aldosterone secretion by 5-HT. Journal of Clinical Endocrinology and Metabolism 2001 86 5001-5007. (doi:10.1210/jcem.86.10.7917.
113. Maltby S, Khazaie K & McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochimica et Biophysica Acta 2009 1796 19-26. (doi:10.1016/j.bbcan.2009.02.001.
114. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB & Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Mycinduced pancreatic islet tumors. Nature Medicine 2007 13 1211-1218. doi:10.1038/nm1649.
115. Duparc C, Moreau L, Felipe Golib Dzib J, Boyer HG, Tetsi Nomigni M, Boutelet I, Boulkroun S, Mukai K, Benecke AG, Amar L et al. Mast cell hyperplasia is associated with aldosterone hypersecretion in a subset of aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 2015 100 E550-E560. (doi:10.1210/jc.2014-3660.
116. Lampron A, Bourdeau I, Oble S, Godbout A, Schurch W, Arjane P, Hamet P & Lacroix A. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. Journal of Clinical Endocrinology and Metabolism 2009 94 750-756. (doi:10.1210/jc.2008-1340.
117. Lacroix A, Tremblay J, Rousseau G, Bouvier M & Hamet P. Propranolol therapy for ectopic b-adrenergic receptors in adrenal Cushing's syndrome. New England Journal of Medicine 1997 337 1429-1434. doi:10.1056/NEJM199711133372004.
118. Albiger NM, Sartorato P, Mariniello B, Iacobone M, Finco I, Fassina A & Mantero F. A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion? European Journal of Endocrinology 2011 164 405-412. (doi:10.1530/EJE-10-0879.
119. Tsagarakis S, Tsigos C, Vassiliou V, Tsiotra P, Pratsinis H, Kletsas D, Trivizas P, Nikou A, Mavromatis T, Sotsiou F et al. Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptidereceptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 2001 86 583-589. (doi:10.1210/jcem.86.2.7171.
120. Leinonen P, Ranta T, Siegberg R, Pelkonen R, Heikkila P & Kahri A. Testosterone-secreting virilizing adrenal adenoma with human chorionic gonadotrophin receptors and 21-hydroxylase deficiency. Clinical Endocrinology 1991 34 31-35. (doi:10.1111/j.1365-2265.1991.tb01732.x.
121. Goodarzi MO, Dawson DW, Li X, Lei Z, Shintaku P, Rao CV & Van-Herle AJ. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 2003 88 73-77. (doi:10.1210/jc.2002-021292.
122. Dahia PL, Ahmed-Shuaib A, Jacobs RA, Chew SL, Honegger J, Fahlbusch R, Besser GM & Grossman AB. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. Journal of Clinical Endocrinology and Metabolism 1996 81 1768-1771. (doi:10.1210/jcem.81.5.8626831.
123. Wang FF, Tang KT, Yen YS, Ho DM, Yang AH, Huang CI, Lin HD & Won JG. Plasma corticotrophin response to desmopressin in patients with Cushing's disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours. Clinical Endocrinology 2012 76 253-263. (doi:10.1111/j.1365-2265.2011.04179.x.
124. Luque RM, Ibanez-Costa A, Lopez-Sanchez LM, Jimenez-Reina L, Venegas-Moreno E, Galvez MA, Villa-Osaba A, Madrazo-Atutxa AM, Japon MA, de la Riva A et al. A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications. Journal of Clinical Endocrinology and Metabolism 2013 98 4160-4169. (doi:10.1210/jc.2013-1992.
125. Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G & Camanni F. Adrenocorticotropin- And cortisolreleasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1997 82 2439-2444. (doi:10.1210/jcem.82.8.4132.
126. Martinez-Fuentes AJ, Moreno-Fernandez J, Vazquez-Martinez R, Duran-Prado M, de la Riva A, Tena-Sempere M, Dieguez C, Jimenez- Reina L, Webb SM, Pumar A et al. Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2006 91 2225-2231. (doi:10.1210/jc.2006-0235).
127. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D & Melmed S. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. Journal of Clinical Investigation 2011 121 4712-4721. (doi:10.1172/JCI60417.
128. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nature Genetics 2015 47 31-38. doi:10.1038/ng.3166.
129. Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, Zhou LF, Mao Y, Li YM, Hu RG, Zhang ZY et al. Recurrent gain-of-function USP8 mutations in Cushing's disease. Cell Research 2015 25 306-317. (doi:10.1038/cr.2015.20.
130. Schorr I, Hinshaw HT, Cooper MA, Mahaffee D & Ney RL. Adenyl cyclase hormone responses of certain human endocrine tumors. Journal of Clinical Endocrinology and Metabolism 1972 34 447-451. (doi:10.1210/jcem-34-3-447.
131. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J et al. Metoclopramide stimulates catecholamine- And granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocrine-Related Cancer 2009 16 281-290. (doi:10.1677/ERC-08-0190.
132. Ziegler CG, Brown JW, Schally AV, Erler A, Gebauer L, Treszl A, Young L, Fishman LM, Engel JB, Willenberg HS et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. PNAS 2009 106 15879-15884. (doi:10.1073/pnas.0907843106.
133. Umahara M, Okada S, Ohshima K & Mori M. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocrine Journal 2003 50 643-650. (doi:10.1507/endocrj.50.643.
134. Occhi G, Losa M, Albiger N, Trivellin G, Regazzo D, Scanarini M, Monteserin-Garcia JL, Frohlich B, Ferasin S, Terreni MR et al. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. Journal ofNeuroendocrinology 2011 23 641-649. (doi:10.1111/j.1365-2826.2011.02155.x.
135. Matsukura S, Kakita T, Hirata Y, Yoshimi H & Fukase M. Adenylate cyclase of GH and ACTH producing tumors of human: activation by non-specific hormones and other bioactive substances. Journal of Clinical Endocrinology and Metabolism 1977 44 392-397. (doi:10.1210/jcem-44-2-392.
136. Lawrence AM, Goldfine ID & Kirsteins L. Growth hormone dynamics in acromegaly. Journal of Clinical Endocrinology and Metabolism 1970 31 239-247. (doi:10.1210/jcem-31-3-239.
137. Hanew K, Kokubun M, Sasaki A, Mouri T & Yoshinaga K. The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly. Journal of Clinical Endocrinology and Metabolism 1980 51 292-297. (doi:10.1210/jcem-51-2-292.
138. Konaka S, Yamada M, Satoh T, Ozawa H, Watanabe E, Takata K & Mori M. Expression of thyrotropin-releasing hormone (TRH) receptor mRNA in somatotrophs in the rat anterior pituitary. Endocrinology 1997 138 827-830. (doi:10.1210/endo.138.2.5030.
139. Arihara Z, Sakurai K, Osaki Y, Fukazawa H, Yamada S, Inoshita N, Murakami O, Ohba K & Takahashi K. ACTH response to desmopressin in a patient with acromegaly; expression of corticotropin-releasing factor, urocortins and vasopressin V1b receptor in GH-producing pituitary adenoma. Endocrine Journal 2011 58 1029-1036. doi:10.1507/endocrj.EJ11-0038.
140. Albiger NM, Ceccato F, Zilio M, Barbot M, Occhi G, Rizzati S, Fassina A, Mantero F, Boscaro M, Iacobone M et al. An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. Clinical Endocrinology 2015 82 808-815. (doi:10.1111/cen.12763.
141. Mazzuco TL, Thomas M, Martinie M, Cherradi N, Sturm N, Feige JJ & Chabre O. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing b-blocker-sensitive Cushing's syndrome. Arquivos Brasileiros de Endocrinologia e Metabologia 2007 51 1452-1462. (doi:10.1590/S0004-27302007000900007.
142. Preumont V, Mermejo LM, Damoiseaux P, Lacroix A & Maiter D. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome. Hormone and Metabolic Research 2011 43 287-291. (doi:10.1055/s-0030-1270523.
143. Karapanou O, Vlassopoulou B, Tzanela M, Stratigou T, Tsatlidis V, Tsirona S & Tsagarakis S. Adrenocorticotropic hormone independent macronodular adrenal hyperplasia due to aberrant receptor expression: is medical treatment always an option? Endocrine Practice 2013 19 e77-e82. (doi:10.4158/EP12346.CR.
144. Daidoh H, Morita H, Hanafusa J, Mune T, Murase H, Sato M, Shibata T, Suwa T, Ishizuka T & Yasuda K. In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTHindependent bilateral macronodular adrenocortical hyperplasia. Clinical Endocrinology 1998 49 403-409. (doi:10.1046/j.1365-2265.1998.00490.x.
145. Nakamura Y, Son Y, Kohno Y, Shimono D, Kuwamura N, Koshiyama H, Sasano H & Matsuda T. Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II. Endocrine 2001 15 57-61. (doi:10.1385/ENDO:15:1:057.
146. Mazzuco TL, Chaffanjon P, Martinie M, Sturm N & Chabre O. Adrenal Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: prediction of the efficacy of b-blockade therapy and interest of unilateral adrenalectomy. Endocrine Journal 2009 56 867-877. (doi:10.1507/endocrj.K08E-370.
147. Fragoso MC, Alencar GA, Lerario AM, Bourdeau I, Almeida MQ, Mendonca BB & Lacroix A. Genetics of primary macronodular adrenal hyperplasia. Journal of Endocrinology 2015 224 R31-R43. (doi:10.1530/JOE-14-0568.
148. Plöckinger U, Tiling N, Blankenstein O, von Weizsäcker K, Allolio B, Kroiss M, Hauptmann K, Saeger W, Radke C, Steinmüller T et al. Transient pregnancy-induced Cushing's syndrome with aberrant adrenal hCG receptor. Experimental and Clinical Endocrinology & Diabetes 2014 122 P137. (doi:10.1055/s-0034-1372154.
149. Lefebvre H, Prévost G & Louiset E. Could targeting hormone receptors be an effective strategy in management of adrenal hyperplasia? International Journal of Endocrine Oncology 2014 1 11-14. (doi:10.2217/ije.14.10.)